DexCom, Inc. (DXCM) is scheduled to release fourth-quarter 2024 results on Feb. 13, after the closing bell. In the last reported quarter, the company’s earnings beat estimates by 4.65%.The bottom line also outpaced the consensus mark in each of the trailing four quarters, delivering an average surprise of 12.43%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Shares of DXCM have gained 23.4% in the past six months compared with the industry’s 4.7% growth. The S&P 500 Index has ralli ...

In its upcoming report, DexCom (DXCM) is predicted by Wall Street analysts to post quarterly earnings of $0.50 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $1.1 billion, representing a year-over-year increase of 6.5%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's ear ...

DexCom (DXCM 0.51%) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels.However, the rising popularity of GLP-1 drugs, which are highly effective in helping people lose weight and also reduce the risk of becoming diabetic, has turned some investors bearish on DexCom's business. If people are slimmer, healthier, and less likely to become diabetic, there would seemingly be less of a need to use CGMs.There's some uncertainty as to how the busin ...

Medical device specialist DexCom (DXCM -0.90%) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to unimpressive financial results, especially in the second and third quarters.However, despite its recent woes, DexCom still looks like an excellent long-term option for growth-oriented investors. In fact, the company could beat the market in the next decade. Read on to find out why.Riding the CGM waveDexCom develops ...

Core Viewpoint - DexCom Inc. (DXCM) has demonstrated strong performance in Q4 and fiscal 2024, leading to a 5.7% increase in stock price, bolstering investor confidence due to impressive revenue growth and a positive outlook for 2025 [1][3] Financial Performance - Preliminary total revenues for Q4 fiscal 2024 reached at least $1.11 billion, marking an 8% increase from Q4 2023 [2] - U.S. revenues were approximately $803 million, a 4% year-over-year rise, while international revenues increased by 17% to around $310 million [2] - For 2025, the Zacks Consensus Estimate projects revenues of $4.60 billion, indicating a year-over-year growth of 14.6% [11] Product and Market Developments - The Stelo platform enhances user experience by integrating real-time glucose data with consumer devices, improving patient engagement and expanding market reach [6] - DexCom has expanded into emerging economies, introducing products like DexCom ONE+ and G7, capitalizing on improved reimbursement policies [7] - Record levels of new customer starts in Japan have been achieved, supported by an expanded sales force [8] - The launch of a proprietary Generative AI platform positions DexCom as a leader in integrating advanced technology into glucose monitoring [9] Strategic Collaborations - Partnerships with companies like OURA aim to revolutionize metabolic health management by combining glucose biosensor data with biometric insights [10] - Collaborations with Tandem Diabetes Care and Insulet enhance CGM offerings and improve health outcomes through integrated insulin delivery systems [14][15] Competitive Landscape - DexCom faces rising competition from Abbott and Senseonics, which could impact market share, particularly in price-sensitive markets [17][18] - The CGM market growth in the U.S. has slowed to approximately 10%, down from over 20%, raising concerns about market saturation [19] Valuation Concerns - DXCM stock is trading at a premium with a forward 12-month P/E of 41.76X compared to the industry average of 33.14X, indicating high growth expectations but also some near-term uncertainties [20] Conclusion - Holding DexCom stock is considered prudent due to robust product innovations and market expansion, despite challenges such as slower market growth and high valuations [22]

Investment Opportunities - The Haggerston BioHealth marketplace channel offers at least 4 exclusive stock tips weekly, focusing on Pharma, Biotech, and Healthcare sectors [1] - The channel provides access to a model portfolio, investment bank-grade financial models, and research for investors [1] DexCom Analysis - DexCom, Inc (NASDAQ: DXCM) was previously covered in September 2023, with reservations expressed about the impact of GLP-1 agonist drugs on the company [2] Biotech Investment Resources - The Haggerston BioHealth group caters to both novice and experienced biotech investors, offering catalysts, buy/sell ratings, product sales forecasts, and market analysis [2] - The group provides integrated financial statements, discounted cash flow analysis, and forecasts for major pharmaceutical companies [2] Analyst Background - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group [2] - Ingham has compiled detailed reports on over 1,000 companies in the biotech, healthcare, and pharma sectors [2]

Group 1: DexCom - DexCom is a leader in the continuous glucose monitoring (CGM) market, which helps diabetes patients track their blood glucose levels [2] - The company faced challenges in 2024, including slower-than-expected revenue growth due to patient rebate eligibility issues, leading to a significant drop in share price [2] - Despite recent difficulties, DexCom's long-term prospects remain strong due to the increasing adoption of CGM devices, which offer advantages over traditional blood glucose meters [3][4] - The total addressable market for DexCom in the U.S. is estimated at 25 million people, indicating substantial growth potential [4] - DexCom has expanded its product offerings with Stelo, an over-the-counter CGM for prediabetes, and its devices are compatible with third-party insulin pens and pumps, enhancing its market position [5] - The combination of growth opportunities and network effects positions DexCom for a rebound and strong returns for investors [5][6] Group 2: Exact Sciences - Exact Sciences specializes in innovative cancer diagnostic tests, with Cologuard being its most popular product for colorectal cancer screening [7] - Cologuard has been used for millions of screenings, contributing to a 13% year-over-year revenue increase to $709 million, although the company remains unprofitable [8] - The FDA approved a new version of Cologuard that performs better and is 5% cheaper to manufacture, which is expected to attract more physicians and reduce costs [9] - There are 60 million eligible unscreened patients in the U.S. aged 45 to 85, presenting a significant market opportunity for Exact Sciences [10] - The company is also developing additional diagnostic devices, including a potential multicancer test, which could lead to stronger revenue growth and profitability in the next five years [10]

Core Insights - DexCom, Inc. reported strong preliminary results for Q4 and full-year 2024, with stock rising 2.7% on January 13, 2025 [1] - The company achieved total revenues of at least $1.11 billion for Q4 2024, an 8% increase from Q4 2023, surpassing the Zacks Consensus Estimate of $1.10 billion [1][2] - For the full year 2024, revenues are estimated at approximately $4.03 billion, reflecting an 11% growth over 2023, slightly above the Zacks Consensus Estimate of $4.02 billion [3] Revenue Breakdown - U.S. revenues reached approximately $803 million, a 4% year-over-year increase, while international revenues climbed 17% to around $310 million [2] - The gross margin faced challenges due to a non-cash charge from inventory damage and production inefficiencies [2] Profitability and Margins - The company anticipates adjusted gross profit and operating margin of approximately 62% and 19% for the full year 2024, indicating resilience amid challenges [4] - For 2025, DexCom projects adjusted gross profit margin between 64% to 65% and an improved adjusted operating margin of approximately 21% [5] Future Outlook - DexCom provided an optimistic revenue outlook for 2025, projecting total revenues of $4.60 billion, representing an estimated growth of 14% over 2024 [5] - Growth drivers include increased sensor volume, ongoing international expansion, and the rollout of the new product, Stelo [5][6] - The company is focused on strategic investments and innovation to strengthen its leadership in the diabetes management solutions market [6] Stock Performance - DexCom's shares have declined 11.8% over the past three months, contrasting with a 15.6% rise in the industry and a 5.9% growth in the S&P 500 [7]

Company Performance - The medical device company is expected to report quarterly earnings of $0.52 per share, reflecting a year-over-year increase of +4% [1] - Revenues are anticipated to reach $1.1 billion, which is a 5.9% increase compared to the same quarter last year [1] - For Edwards Lifesciences, the consensus EPS estimate has been adjusted to $0.55, indicating a -14.1% change from the previous year [3] Stock Movement - DexCom shares increased by 5.6% in the last trading session, closing at $80.04, with notable trading volume [2] - Edwards Lifesciences closed 1.2% higher at $74.81, with a 5% return over the past month [5] - The positive trend in earnings estimate revisions for DexCom suggests potential price appreciation in the future [7] Industry Context - The rise in DexCom's stock is linked to Novo Nordisk's disappointing results from its weight-loss drug study, which shifted investor sentiment favorably towards diabetes device companies [6] - The Zacks Medical - Instruments industry includes both DexCom and Edwards Lifesciences, with both companies currently holding a Zacks Rank of 3 (Hold) [2][3]

Core Viewpoint - DexCom's stock has declined by 37% this year due to disappointing second-quarter results, highlighting both short-term challenges and long-term concerns for the company's prospects [1] Group 1: Company Overview - DexCom specializes in developing continuous glucose monitoring (CGM) systems aimed at helping diabetes patients track their blood glucose levels, which has historically improved health outcomes and driven revenue growth [2] - The company has an installed base of 1.7 million customers as of 2022, with an estimated 25 million people in the U.S. with type 2 diabetes who have not yet progressed to insulin therapy, representing a significant market opportunity [15] Group 2: Market Challenges - DexCom faces potential long-term challenges from emerging diabetes therapies, including those in development that may reduce the target market for CGM devices, particularly for type 1 diabetes patients [12][13] - The company’s current forward price-to-earnings ratio stands at 44, significantly higher than the healthcare industry average of 17, indicating that the stock has historically been viewed as expensive [5] Group 3: Market Opportunities - DexCom is expanding its addressable market by targeting patients not on insulin therapy, including those with type 2 diabetes and pre-diabetes, following FDA clearance of its Stelo CGM option [3] - The introduction of a proprietary generative AI platform integrated into its devices, starting with Stelo, aims to enhance patient decision-making by analyzing data and lifestyle patterns, potentially attracting a broader patient base [9] - The growing awareness of CGM technology and its application in similar populations in other countries could sustain DexCom's financial performance, even amid potential market contractions from new therapies [10]